Structured Treatment Interruption: Approaches and Risks (Q34583760)

3 August 2017

Structured Treatment Interruption: Approaches and Risks (English)

1 reference

3 August 2017

1

Mark Dybul

1 reference

3 August 2017

1 April 2002

1 reference

Current infectious disease reports

3 August 2017

1 reference

3 August 2017

4

1 reference

3 August 2017

2

1 reference

3 August 2017

175-180

1 reference

Crystalluria and urinary tract abnormalities associated with indinavir

3 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11908-002-0059-2

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-002-0059-2

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-002-0059-2

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-002-0059-2

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

21 January 2018

1 reference

12 December 2020

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

1 reference

12 December 2020

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

12 December 2020

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

1 reference

12 December 2020

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

1 reference

12 December 2020

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy

1 reference

12 December 2020

High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation

1 reference

12 December 2020

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

12 December 2020

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

1 reference

12 December 2020

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

12 December 2020

Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine

1 reference

12 December 2020

Acute pancreatitis. A fatal complication of AIDS therapy

1 reference

12 December 2020

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

1 reference

12 December 2020

PUBLIC HEALTH: HIV/AIDS Treatment for Millions

1 reference

12 December 2020

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

12 December 2020

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

12 December 2020

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection.

1 reference

12 December 2020

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda

1 reference

12 December 2020

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters

1 reference

12 December 2020

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

1 reference

12 December 2020

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

1 reference

12 December 2020

Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.

1 reference

12 December 2020

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group

1 reference

12 December 2020

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

1 reference

12 December 2020

Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy

1 reference

12 December 2020

Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression

1 reference

12 December 2020

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

12 December 2020

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.

1 reference

12 December 2020

HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals

1 reference

12 December 2020

Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection

1 reference

12 December 2020

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

1 reference

12 December 2020

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

1 reference

12 December 2020

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

1 reference

12 December 2020

HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy

1 reference

12 December 2020

Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases

1 reference

12 December 2020

Control of HIV despite the Discontinuation of Antiretroviral Therapy

1 reference

12 December 2020

Immune control of HIV-1 after early treatment of acute infection

1 reference

12 December 2020

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection

1 reference

12 December 2020

Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?

1 reference

12 December 2020

Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques

1 reference

12 December 2020

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

1 reference

12 December 2020

CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsivene

1 reference

12 December 2020

Adherence in AIDS clinical trials: a framework for clinical research and clinical care

1 reference

12 December 2020

10.1007/S11908-002-0059-2

Identifiers

DOI

1 reference

release_tfjxswkrenhulm6ln7yi6zbm6y

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tfjxswkrenhulm6ln7yi6zbm6y

24 November 2022

mapped directly with Wikidata item

PubMed ID

11927050

1 reference

PubMed ID

11927050